Tau-specific PET ligands have demonstrated encouraging results in Alzheimer’s disease (AD) [28] [29] and detected the progression of AD tauopathy among individuals along the cognitive spectrum [30]. This evidence concerns the gene MAPT and Alzheimer disease.